Lymphoma Rounds: New York – October 18, 2022

Professional Education

This New York Lymphoma Rounds provides a forum for local practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Physicians share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the local area. Please note that this program is only open to practicing lymphoma physicians and industry supporters. Please continue to check this page for updates. For updates, please ensure you are subscribed to receive emails from the Lymphoma Research Foundation

Full Lymphoma Rounds COVID policy can be accessed here and required for review prior to submitting a registration.

Lymphoma Rounds: New York

Date: Tuesday, October 18, 2022
Time: Networking 6:30 PM ET
Program 7:00 PM – 8:30 PM ET
Location: Sheraton New York Times Square
811 7th Avenue, W 53rd Street
New York, NY 10019

This program is free for healthcare professionals; however, pre-registration is required.

Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Eva Migliore, LRF, at emigliore@lymphoma.orgVirtual Exhibit opportunities are available.

Companies that have secured a national exhibit sponsorship for Lymphoma Rounds must still rsvp by emailing Eva Migliore (emigliore@lymphoma.org) at least one week before the program to confirm their attendance.

PROGRAM AGENDA – TBA

This meeting will be held in conjunction with the LYMPHOMA & MYELOMA CONGRESS – October 18-22, 2022

ABOUT THE PROGRAM
The Lymphoma Rounds program provides a forum for local practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Physicians share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the local area.

At the conclusion of this educational activity, the participant should be better able to:

  • Summarize the latest developments in lymphoma diagnosis, treatment and management.
  • Apply best practices for treating lymphoma patients.
  • Inform patients about potential clinical trial opportunities.
  • Establish a network of health care professionals who work with lymphoma patients.

This is the first program in the 2022-23 New York Rounds series.

NEW YORK Lymphoma Rounds Steering Committee

Columbia University Medical Center
Jennifer Amengual, MD
Andrew Lipsky, MD
Barbara Pro, MD
Hackensack University Medical Center
Andre Goy, MD, MS
Ichan School of Medicine at Mount Sinai
Suchitra Sundaram, MD
Memorial Sloan Kettering Cancer Center
Jennifer Lue, MD
Anthony Mato, MD, MSCE
David Straus, MD (chair)
NYU Langone Medical Center
Catherine Diefenbach, MD
Rutgers Cancer Institute of New Jersey
Kevin David, MD
Weill Cornell Medicine
Ethel Cesarman, MD, PhD
Amy Chadburn, MD
Morton Coleman, MD
Yale University School of Medicine
Francine Foss, MD

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Lymphoma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Statement

Penn State College of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provided by:
Lymphoma Research Foundation and the Penn State College of Medicine

This activity is supported by educational grants from:
AbbVie, Inc., ADC Therapeutics, AstraZeneca, BTG International Inc., Lilly Oncology, and Seagen